The genetics-first
drug company.
We develop drugs for targets with proven genetic causality. No more failed trials. Only validated mechanisms.
Drug Development is Broken
The industry doesn't have a drug design problem. It has a target selection problem. Companies keep picking targets without genetic validation, then act surprised when trials fail.
Our Approach
We only pursue targets where human genetics proves the mechanism.
Genetic Validation First
Every target in our pipeline has causal genetic evidence. No speculation. No "promising preclinical data." Proof.
Quantified Probability
We know our success probability for each program. Not "high confidence" - actual numbers with uncertainty bounds.
Portfolio Optimization
We allocate capital to programs with the highest expected value. Ruthless prioritization based on genetic evidence strength.
We Prove It Publicly
We make predictions on other companies' trials before outcomes are known. Preregistered. Timestamped. Verifiable.
Backtest on 2023-2024 trials: 5/5 correct. If we can predict their outcomes, imagine what we can do with our own programs.
"Genetically-supported targets have 2x higher clinical success rates"Nelson et al., Nature Genetics 2015 — validated by King 2019, Minikel 2024
This is the most robust finding in drug development. We're the company built to exploit it.
Any Disease With Genetic Evidence
Single-gene disorders with clear causal variants. Highest confidence targets.
Polygenic diseases where GWAS + MR identifies causal genes from risk loci.
Targets validated across eQTL, pQTL, mQTL, and sQTL for converging evidence.
Disease-modifying therapies only. We don't do symptomatic treatments.
The next generation of drug development.
Built on genetic proof, not hope.